Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

Inclusion Criteria Concurrent Medication: Allowed: * PCP prophylaxis. * Topical antifungal agents, clotrimazole troches, nystatin oral suspension, topical ketoconazole, and oral fluconazole. * Acyclovir (\<= 1000 mg/day) as maintenance therapy for herpes simplex virus. * Recombinant erythropoietin and G-CSF. * Antibiotics for bacterial infections, unless specifically excluded. * Symptomatic treatment such as antipyretics, analgesics, nonsteroidal anti-inflammatory agents, and antiemetics. * Antacids. Patients must have: * HIV-1 infection. * CD4 count 200 - 500 cells/mm3. * Either no prior antiretroviral therapy or discontinued AZT monotherapy 3 or more weeks prior to study entry. NOTE: * Half of patients should be antiretroviral naive. Prior Medication: Allowed: * Prior AZT. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malignancy other than minimal Kaposi's sarcoma. Concurrent Medication: Excluded: * Rifabutin. * Rifampin. * Terfenadine. * Astemizole. * Loratadine. * Trifluoperazine. * Piperazine citrate. * Any acute or chronic therapy for CMV, MAC, toxoplasmosis, or disseminated fungal infection. * Non-study antiretroviral therapies, interferons, biologic response modifiers, and HIV vaccines. * Systemic corticosteroids for more than 21 consecutive days. * Foscarnet. * Systemic cytotoxic chemotherapy for a malignancy. Patients with the following prior conditions are excluded: * History of pancreatitis (in patients who received prior AZT). * History of grade 2 or worse peripheral neuropathy (in patients who received prior AZT). * History of hypersensitivity to BHAP compounds (e.g., trifluoperazine - Stelazine, piperazine citrate - Antepar). Prior Medication: Excluded within 30 days prior to study entry: * Any investigational medication. * Interferon. * Interleukin. * Rifabutin. * Rifampin. * Terfenadine. * Astemizole. * Loratadine. * Trifluoperazine. * Piperazine citrate. Excluded at any time: * Prior ddI, ddC, d4T, or 3TC. * Prior foscarnet. * Prior BHAP compound or other non-nucleoside RT inhibitor. Active substance abuse interfering with compliance.